AD 452: Development discontinued

Sosei discontinued development of AD 452 for RA after the compound missed the primary endpoint of ACR20 response

Read the full 189 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE